Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 20 Show results per page	View Search Criteria \| Help With Results


1.		MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				Pharmaceutical / Industry				MDX010-20 NCT00094653


2.		Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				Pharmaceutical / Industry				CA184-024 NCT00324155

Last Modified: 8/11/2006 First Published: 3/24/2003


3.		Phase I/II Study of Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody (MDX-CTLA4) and High-Dose Interleukin-2 in Patients With Metastatic Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Completed				16 and over				NCI				NCI-03-C-0109 NCT00058279

Last Modified: 9/17/2008 First Published: 7/23/2004


4.		Phase I/II Study of Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody (MDX-010) in Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				18 and over				NCI				MAYO-MC0312 NCI-6359, 6359, NCT00089076, UCLA-0406055-01

Last Modified: 5/11/2006 First Published: 3/1/2002


5.		Phase II Study of Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody (MDX-010) Combined With gp100 Peptides Emulsified in Montanide ISA-51 in Patients With Stage IV Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				16 and over				NCI				NCI-02-C-0106H NCI-5743, 5743, NCT00032045

Last Modified: 1/8/2009 First Published: 3/24/2003


6.		Phase II Study of Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody (MDX-010) in Patients With Metastatic Clear Cell Renal Cancer Who Are Refractory to or Ineligible for Interleukin-2

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				16 and over				NCI				NCI-03-C-0094 NCT00057889

Last Modified: 1/8/2009 First Published: 1/23/2004


7.		Phase II Randomized Study of Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody (MDX-010) With or Without gp100 Peptides Emulsified in Montanide ISA-51 in Patients With Stage IV Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				16 and over				NCI				NCI-04-C-0083 MDX-010-19, NCI-6532, 6532, NCT00077532


8.		Comparison Study of MDX-010 (CTLA-4) Alone and Combined With Docetaxel in the Treatment of Patients With Hormone Refractory Prostate Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				Pharmaceutical / Industry				MDX010-07 NCT00050596


9.		Study of MDX-010 in Stage IV Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				Pharmaceutical / Industry				MDX010-12 NCT00083278

Last Modified: 12/18/2008 First Published: 5/23/2005


10.		Phase II Study of Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody (MDX-010) in Patients With Unresectable Stage IV (Locally or Distantly Metastatic) Pancreatic Adenocarcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				NCI				NCI-05-C-0141 NCI-P6557, MDX-010-24, NCT00112580

Select All on One Page


					1 2 Next >

| | | | | | | |

A Service of the National Cancer Institute